Covered recipient · General Payments record
RANEE MEHRA
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$4,211.09
5 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $4,050.00 | 2 |
| Food and Beverage | $161.09 | 3 |
By paying entity
PY2022 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Coherus Biosciences Inc. | $4,171.44 | 3 |
| EISAI INC. | $23.36 | 1 |
| Gilead Sciences, Inc. | $16.29 | 1 |
Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
RANEE MEHRA
NPI 1760411326 · CMS profile ID 170140
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
BALTIMORE, MD
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1760411326?year=2022&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- RANEE MEHRA, NPI 1760411326, CMS profile ID 170140. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1760411326?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). RANEE MEHRA, NPI 1760411326, CMS profile ID 170140. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1760411326?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- RANEE MEHRA, NPI 1760411326, CMS profile ID 170140, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1760411326?year=2022&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
5 matching records · $4,211.09 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–5 of 5.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| EISAI INC. | $23.36 | 08/23/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 908078449 | CMS |
| Coherus Biosciences Inc. | $121.44 | 06/05/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 956565101 | CMS |
| Coherus Biosciences Inc. | $1,687.50 | 04/28/2022 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 956565039 | CMS |
| Gilead Sciences, Inc. | $16.29 | 03/25/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 929559295 | CMS |
| Coherus Biosciences Inc. | $2,362.50 | 02/24/2022 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 956565053 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2022, 2023, 2024, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,124,333.75 | 93 |
| PY2024 | Principal investigator | $813,892.28 | 61 |
| PY2023 | Principal investigator | $633,471.41 | 125 |
| PY2022 | Principal investigator | $830,697.81 | 139 |
| PY2021 | Recipient | $330.00 | 1 |
| PY2021 | Principal investigator | $979,164.73 | 91 |
| PY2020 | Principal investigator | $622,730.93 | 67 |
| PY2019 | Principal investigator | $214,554.45 | 14 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
93 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $17,540.72 | 12/31/2025 | Non-covered Recipient Entity University of Maryland | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma LA HNSCC | No dispute reported | 06/30/2026 | 1232926441 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $10,300.50 | 12/31/2025 | Non-covered Recipient Entity University of Maryland Greenebaum Cancer Center | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with r | No dispute reported | 06/30/2026 | 1232939901 |
| Principal investigator 1 | Janssen Research & Development, LLC | $19,460.00 | 12/22/2025 | Non-covered Recipient Entity UNIVERSITY OF MARYLAND BALTIMORE | A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1175383311 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $312.45 | 12/19/2025 | Non-covered Recipient Entity State of Maryland | Head And Neck Cancer Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1199911687 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $640.71 | 12/18/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF MARYLAND MED SYS | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223272225 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,006.15 | 12/16/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF MARYLAND MED SYS | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223272223 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,025.50 | 12/11/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF MARYLAND MED SYS | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223272221 |
| Principal investigator 1 | Coherus Oncology, Inc. | $45,039.40 | 12/05/2025 | Non-covered Recipient Entity State of Maryland | SRF114-101 | No dispute reported | 06/30/2026 | 1235252433 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $2,111.40 | 12/05/2025 | Non-covered Recipient Entity UNIVERSITY OF MARYLAND BALTIMORE | 101623 | No dispute reported | 06/30/2026 | 1252498491 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $26,146.90 | 12/01/2025 | Non-covered Recipient Entity UNIVERSITY OF MARYLAND BALTIMORE | 101623 | No dispute reported | 06/30/2026 | 1252498601 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $11,740.40 | 11/24/2025 | Non-covered Recipient Entity University of Maryland | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma LA HNSCC | No dispute reported | 06/30/2026 | 1232926439 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $3,534.30 | 11/18/2025 | Non-covered Recipient Entity State of Maryland | Head And Neck Cancer Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1199911685 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $975.00 | 11/14/2025 | Non-covered Recipient Entity UNIVERSITY OF MARYLAND BALTIMORE | 81990 | No dispute reported | 06/30/2026 | 1252498589 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $1,726.00 | 11/14/2025 | Non-covered Recipient Entity UNIVERSITY OF MARYLAND BALTIMORE | 81990 | No dispute reported | 06/30/2026 | 1252498591 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $1,560.00 | 11/14/2025 | Non-covered Recipient Entity UNIVERSITY OF MARYLAND BALTIMORE | 81990 | No dispute reported | 06/30/2026 | 1252498593 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,832.00 | 11/10/2025 | Non-covered Recipient Entity UNIVERSITY OF MARYLAND BALTIMORE | A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1175383403 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $16,435.00 | 11/06/2025 | Non-covered Recipient Entity University of Maryland Greenebaum Cancer Center | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with r | No dispute reported | 06/30/2026 | 1232939899 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $34,020.00 | 10/14/2025 | Non-covered Recipient Entity University of Maryland Medical Group | A PHASE 2 STUDY OF ALX148 IN COMBINATION WITH PEMBROLIZUMAB AND CHEMOTHERAPY IN PATIENTS WITH ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA | No dispute reported | 06/30/2026 | 1232935791 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $25,351.30 | 10/08/2025 | Non-covered Recipient Entity UNIVERSITY OF MARYLAND BALTIMORE | 101623 | No dispute reported | 06/30/2026 | 1252498597 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $15,602.58 | 10/06/2025 | Non-covered Recipient Entity State of Maryland | Head And Neck Cancer Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1199911683 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,538.00 | 10/06/2025 | Non-covered Recipient Entity UNIVERSITY OF MARYLAND BALTIMORE | A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1175383361 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $30,940.00 | 10/01/2025 | Non-covered Recipient Entity UNIVERSITY OF MARYLAND BALTIMORE | 101623 | No dispute reported | 06/30/2026 | 1252498595 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $650.00 | 10/01/2025 | Non-covered Recipient Entity UNIVERSITY OF MARYLAND BALTIMORE | 101623 | No dispute reported | 06/30/2026 | 1252498599 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $1,625.00 | 10/01/2025 | Non-covered Recipient Entity UNIVERSITY OF MARYLAND BALTIMORE | 101623 | No dispute reported | 06/30/2026 | 1252498603 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $241.80 | 09/26/2025 | Non-covered Recipient Entity UNIVERSITY OF MARYLAND BALTIMORE | 101623 | No dispute reported | 06/30/2026 | 1252497871 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,092.00 | 09/22/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF MARYLAND MED SYS | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223272219 |
| Principal investigator 1 | Janssen Research & Development, LLC | $530.00 | 09/15/2025 | Non-covered Recipient Entity UNIVERSITY OF MARYLAND BALTIMORE | A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1175383116 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,573.00 | 09/15/2025 | Non-covered Recipient Entity UNIVERSITY OF MARYLAND BALTIMORE | A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1175383438 |
| Principal investigator 1 | Incyte Corporation | $4,964.75 | 09/11/2025 | Non-covered Recipient Entity U OF MARYLAND - GREENEBAUM CANCER CTR | A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | No dispute reported | 06/30/2026 | 1240609165 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,529.76 | 09/10/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF MARYLAND MED SYS | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223272217 |
| Principal investigator 1 | Janssen Research & Development, LLC | $27,859.55 | 09/08/2025 | Non-covered Recipient Entity UNIVERSITY OF MARYLAND BALTIMORE | A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1175383133 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $528.53 | 09/04/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF MARYLAND MED SYS | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223272215 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $2,656.25 | 08/15/2025 | Non-covered Recipient Entity UNIVERSITY OF MARYLAND BALTIMORE | 101623 | No dispute reported | 06/30/2026 | 1252497695 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,933.00 | 08/14/2025 | Non-covered Recipient Entity UNIVERSITY OF MARYLAND BALTIMORE | A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1175383296 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $640.71 | 08/13/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF MARYLAND MED SYS | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223272213 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $1,693.44 | 08/04/2025 | Non-covered Recipient Entity State of Maryland | A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) | No dispute reported | 06/30/2026 | 1199911665 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $259.76 | 08/04/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF MARYLAND MED SYS | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223272211 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,269.10 | 07/31/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF MARYLAND MED SYS | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223272203 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,807.30 | 07/31/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF MARYLAND MED SYS | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223272205 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $599.20 | 07/31/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF MARYLAND MED SYS | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223272207 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,269.10 | 07/31/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF MARYLAND MED SYS | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223272209 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,092.00 | 07/28/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF MARYLAND MED SYS | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223272201 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $599.20 | 07/24/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF MARYLAND MED SYS | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223272197 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $6,345.50 | 07/24/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF MARYLAND MED SYS | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223272199 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $1,050.00 | 07/21/2025 | Non-covered Recipient Entity State of Maryland | A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) | No dispute reported | 06/30/2026 | 1199911659 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $35,303.14 | 07/16/2025 | Non-covered Recipient Entity UNIVERSITY OF MARYLAND BALTIMORE | 81990 | No dispute reported | 06/30/2026 | 1252497867 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $56,764.82 | 07/16/2025 | Non-covered Recipient Entity UNIVERSITY OF MARYLAND BALTIMORE | 81990 | No dispute reported | 06/30/2026 | 1252497869 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,198.06 | 07/15/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF MARYLAND MED SYS | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223272195 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $8,595.97 | 07/14/2025 | Non-covered Recipient Entity State of Maryland | A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) | No dispute reported | 06/30/2026 | 1199911661 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $3,342.78 | 07/07/2025 | Non-covered Recipient Entity State of Maryland | A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) | No dispute reported | 06/30/2026 | 1199911667 |
| Principal investigator 1 | PFIZER INC. | $5,504.80 | 07/01/2025 | Non-covered Recipient Entity UNIVERSITY OF MARYLAND | A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 | No dispute reported | 06/30/2026 | 1228840922 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $8,050.00 | 06/23/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF MARYLAND MED SYS | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223272191 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $9,179.10 | 06/18/2025 | Non-covered Recipient Entity State of Maryland | A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) | No dispute reported | 06/30/2026 | 1199911675 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,281.42 | 06/17/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF MARYLAND MED SYS | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223272189 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $1,868.00 | 06/13/2025 | Non-covered Recipient Entity UNIVERSITY OF MARYLAND BALTIMORE | 81990 | No dispute reported | 06/30/2026 | 1252496065 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $7,907.15 | 06/11/2025 | Non-covered Recipient Entity UNIVERSITY OF MARYLAND BALTIMORE | 101623 | No dispute reported | 06/30/2026 | 1252496207 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,923.00 | 06/09/2025 | Non-covered Recipient Entity UNIVERSITY OF MARYLAND BALTIMORE | A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1175383108 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $1,050.00 | 06/05/2025 | Non-covered Recipient Entity State of Maryland | A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) | No dispute reported | 06/30/2026 | 1199911669 |
| Principal investigator 1 | Amgen Inc. | $363,420.48 | 06/03/2025 | Non-covered Recipient Entity UNIVERSITY OF MARYLAND MEDICAL CENTER | Expanded Access request for Tarlatamab to treat a 45 y.o. Female Patient with DLL3+ High grade Neuroendocrine Tumor of the Lung | No dispute reported | 06/30/2026 | 1246650444 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $12,666.00 | 06/02/2025 | Non-covered Recipient Entity UNIVERSITY OF MARYLAND BALTIMORE | 81990 | No dispute reported | 06/30/2026 | 1252496195 |
| Principal investigator 1 | PFIZER INC. | $32,233.60 | 06/02/2025 | Non-covered Recipient Entity UNIVERSITY OF MARYLAND | A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 | No dispute reported | 06/30/2026 | 1228845979 |
| Principal investigator 1 | PFIZER INC. | $1,708.00 | 06/02/2025 | Non-covered Recipient Entity UNIVERSITY OF MARYLAND | A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 | No dispute reported | 06/30/2026 | 1228846077 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $38.25 | 05/16/2025 | Non-covered Recipient Entity UNIVERSITY OF MARYLAND BALTIMORE | 81990 | No dispute reported | 06/30/2026 | 1252495877 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $780.00 | 05/16/2025 | Non-covered Recipient Entity UNIVERSITY OF MARYLAND BALTIMORE | 81990 | No dispute reported | 06/30/2026 | 1252496201 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $2,145.00 | 05/16/2025 | Non-covered Recipient Entity UNIVERSITY OF MARYLAND BALTIMORE | 81990 | No dispute reported | 06/30/2026 | 1252496203 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $5,041.00 | 05/16/2025 | Non-covered Recipient Entity UNIVERSITY OF MARYLAND BALTIMORE | 81990 | No dispute reported | 06/30/2026 | 1252496205 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $5,041.00 | 05/14/2025 | Non-covered Recipient Entity UNIVERSITY OF MARYLAND BALTIMORE | 101623 | No dispute reported | 06/30/2026 | 1252496209 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $585.00 | 05/14/2025 | Non-covered Recipient Entity UNIVERSITY OF MARYLAND BALTIMORE | 101623 | No dispute reported | 06/30/2026 | 1252496211 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $3,080.70 | 05/12/2025 | Non-covered Recipient Entity State of Maryland | A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) | No dispute reported | 06/30/2026 | 1199911677 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,950.00 | 05/01/2025 | Non-covered Recipient Entity UNIVERSITY OF MARYLAND BALTIMORE | A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1175383262 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $13,140.61 | 04/29/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF MARYLAND MED SYS | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223272183 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $21,411.10 | 04/25/2025 | Non-covered Recipient Entity UNIVERSITY OF MARYLAND BALTIMORE | 101623 | No dispute reported | 06/30/2026 | 1252495879 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,595.61 | 04/16/2025 | Non-covered Recipient Entity State of Maryland | A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) | No dispute reported | 06/30/2026 | 1199911671 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $490.14 | 04/11/2025 | Non-covered Recipient Entity State of Maryland | A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) | No dispute reported | 06/30/2026 | 1199911673 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $871.13 | 04/08/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF MARYLAND MED SYS | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223272181 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $1,755.00 | 04/02/2025 | Non-covered Recipient Entity UNIVERSITY OF MARYLAND BALTIMORE | 81990 | No dispute reported | 06/30/2026 | 1252496197 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $1,726.00 | 04/02/2025 | Non-covered Recipient Entity UNIVERSITY OF MARYLAND BALTIMORE | 81990 | No dispute reported | 06/30/2026 | 1252496199 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $126.00 | 03/20/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF MARYLAND MED SYS | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223272175 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,003.72 | 03/19/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF MARYLAND MED SYS | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223272173 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $2,571.68 | 03/04/2025 | Non-covered Recipient Entity State of Maryland | A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) | No dispute reported | 06/30/2026 | 1199911681 |
| Principal investigator 1 | Incyte Corporation | $5,529.50 | 02/27/2025 | Non-covered Recipient Entity U OF MARYLAND - GREENEBAUM CANCER CTR | A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS great than or equal to 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | No dispute reported | 06/30/2026 | 1240609168 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $7,448.32 | 02/24/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF MARYLAND MED SYS | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223272171 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $5,856.00 | 02/21/2025 | Non-covered Recipient Entity UNIVERSITY OF MARYLAND BALTIMORE | 81990 | No dispute reported | 06/30/2026 | 1252496461 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $2,111.00 | 02/21/2025 | Non-covered Recipient Entity UNIVERSITY OF MARYLAND BALTIMORE | 81990 | No dispute reported | 06/30/2026 | 1252496597 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $23,394.00 | 02/21/2025 | Non-covered Recipient Entity UNIVERSITY OF MARYLAND BALTIMORE | 81990 | No dispute reported | 06/30/2026 | 1252496599 |
| Principal investigator 1 | Janssen Research & Development, LLC | $41,736.00 | 02/17/2025 | Non-covered Recipient Entity UNIVERSITY OF MARYLAND BALTIMORE | A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1175383344 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $826.20 | 02/12/2025 | Non-covered Recipient Entity UNIVERSITY OF MARYLAND BALTIMORE | 101623 | No dispute reported | 06/30/2026 | 1252496341 |
| Principal investigator 1 | Iovance Biotherapeutics, Inc. | $1,950.00 | 01/29/2025 | Non-covered Recipient Entity UNIVERSITY OF MARYLAND BALTIMORE | 81990 | No dispute reported | 06/30/2026 | 1252496463 |
| Principal investigator 1 | Amgen Inc. | $2,539.93 | 01/27/2025 | Non-covered Recipient Entity UNIVERSITY OF MARYLAND MEDICAL CENTER | A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of AMG 193 in Subjects With Methylthioadenosine Phosphorylase (MTAP)-Deleted Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1246650432 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $17,525.74 | 01/27/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF MARYLAND MED SYS | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223272163 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $17,525.74 | 01/27/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF MARYLAND MED SYS | AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223272165 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $3,187.80 | 01/07/2025 | Non-covered Recipient Entity State of Maryland | A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) | No dispute reported | 06/30/2026 | 1199911663 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $1,708.00 | 01/07/2025 | Non-covered Recipient Entity State of Maryland | A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN) | No dispute reported | 06/30/2026 | 1199911679 |